Insider Selling: Beta Bionics (NASDAQ:BBNX) Director Sells 998 Shares of Stock

Beta Bionics, Inc. (NASDAQ:BBNX) Director Adam Lezack sold 998 shares of the company’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $11.21, for a total transaction of $11,187.58. Following the transaction, the director directly owned 27,399 shares in the company, valued at approximately $307,142.79. This trade represents a 3.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adam Lezack also recently made the following trade(s):

• On Thursday, May 21st, Adam Lezack sold 1,000 shares of Beta Bionics stock. The stock was sold at an average price of $9.95, for a total transaction of $9,950.00.

Beta Bionics Trading Down 0.8%

Shares of NASDAQ:BBNX traded down $0.10 on Tuesday, reaching $11.72. 795,893 shares of the company were exchanged, compared to its average volume of 1,168,092. Beta Bionics, Inc. has a 1-year low of $8.80 and a 1-year high of $32.71. The firm has a market cap of $522.24 million, a price-to-earnings ratio of -7.76 and a beta of 3.29. The company has a 50-day moving average of $10.62 and a 200-day moving average of $18.03.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings results on Tuesday, April 21st. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. The business had revenue of $27.63 million for the quarter. As a group, analysts forecast that Beta Bionics, Inc. will post -2.19 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Robert W. Baird lowered their price objective on shares of Beta Bionics from $28.00 to $14.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 18th. Stifel Nicolaus lowered their price objective on shares of Beta Bionics from $22.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. UBS Group raised shares of Beta Bionics to a “strong-buy” rating in a research note on Monday, February 9th. Weiss Ratings cut shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. Finally, Bank of America lowered their price objective on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a research note on Monday, May 18th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Institutional Investors Weigh In On Beta Bionics

A number of large investors have recently added to or reduced their stakes in BBNX. Essex Investment Management Co. LLC purchased a new position in Beta Bionics in the 3rd quarter valued at about $4,423,000. JPMorgan Chase & Co. lifted its holdings in Beta Bionics by 3,238.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 205,955 shares of the company’s stock valued at $4,092,000 after purchasing an additional 199,785 shares in the last quarter. Pura Vida Investments LLC lifted its holdings in Beta Bionics by 11,150.0% in the 3rd quarter. Pura Vida Investments LLC now owns 281,250 shares of the company’s stock valued at $5,588,000 after purchasing an additional 278,750 shares in the last quarter. Farallon Capital Management LLC lifted its holdings in Beta Bionics by 2.6% in the 3rd quarter. Farallon Capital Management LLC now owns 4,313,920 shares of the company’s stock valued at $85,718,000 after purchasing an additional 110,000 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in Beta Bionics in the 4th quarter valued at about $4,579,000.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.